Is Relmada Therapeutics, Inc. profitable?

Relmada Therapeutics, Inc. is not currently profitable: it reported a net loss of $58.9M over the trailing twelve months.

What is Relmada Therapeutics, Inc.'s earnings per share?

Relmada Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-1.11.

Where does Relmada Therapeutics, Inc.'s income statement data come from?

Every line is extracted from Relmada Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Relmada Therapeutics, Inc. RLMD Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Research and development	$26.88M-41.8%	$46.18M-15.7%	$54.81M-51.6%	$113.32M+25.1%
General and administrative	$32.22M-14.6%	$37.72M-22.9%	$48.89M+2.0%	$47.93M+36.6%
Compensation and benefits	$13.91M-53.9%	$30.18M-31.1%	$43.81M-0.9%	$44.19M+9.1%
Occupancy and equipment	$190.7K-19.5%	$236.9K+5.1%	$225.5K—	——
Other operating expenses	$59.1M-29.6%	$83.89M-19.1%	$103.7M-35.7%	$161.25M+28.3%
Total operating expenses	$59.1M-29.6%	$83.89M-19.1%	$103.7M-35.7%	$161.25M+28.3%
Operating income	-$59.1M+29.6%	-$83.89M+19.1%	-$103.7M+35.7%	-$161.25M-28.3%
Interest income	$1.4M-60.5%	$3.53M-31.5%	$5.15M—	——
Other income (expense), net	$1.72M-56.2%	$3.91M-20.3%	$4.91M+16.8%	$4.21M+8,803%
Net investment gains (losses)	-$79.21K-121%	$374.93K+109%	-$4.06M-594%	-$585.52K+7.9%
Net income	-$57.39M+28.3%	-$79.98M+19.0%	-$98.79M+37.1%	-$157.04M-24.9%
Diluted earnings per share	-$1.47+44.5%	-$2.65+19.0%	-$3.27+38.3%	-$5.30+25.8%
Basic earnings per share	-$1.47+44.5%	-$2.65+19.0%	-$3.27+38.3%	-$5.30+25.8%
Weighted-average shares, diluted	136.3M+13.0%	120.6M+0.2%	120.4M+2.0%	118M+71.9%
Weighted-average shares, basic	136.3M+13.0%	120.6M+0.2%	120.4M—	——
APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition	$13.91M-53.9%	$30.18M-31.1%	$43.81M-0.9%	$44.19M—
Pre-tax stock-based compensation cost	$14.81M-50.9%	$30.18M-31.1%	$43.81M-0.9%	$44.19M+9.1%
Stock options excluded as their inclusion would be anti-dilutive (in shares)	——	——	——	——
Business development	——	——	——	——
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect	——	——	——	——
Cashless Exercise Of Warrant For Common Stock	——	——	——	——
Cashless Exercise Of Warrants	——	——	——	——
Corporate Security	——	——	——	——
Defined Contribution Plan Cost Recognized	$176.37K+30.4%	$135.3K-4.0%	$140.98K—	——
Defined Contribution Plan Employer Matching Contribution Percent Of Match	——	——	——	——
Maximum percentage of annual compensation contributed by the participant (percent)	——	——	——	——
Effective tax rates	$0—	$0—	$0—	$0—
Effective Income Tax Rate Reconciliation Adjustments To NOL Due To382Percentage	——	——	——	——
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent	——	——	——	——
Effective Income Tax Rate Reconciliation Changes In Unrecognized Tax Benefits Percentage	——	——	——	——
Nontaxable or nondeductible items	——	——	——	——
Effective Income Tax Rate Reconciliation Other Reconciling Items Percent	——	——	——	——
Effective Income Tax Rate Reconciliation Permanent Trueups	——	——	——	——
Excess tax benefits associated with employee equity plans (in percent)	——	——	——	——
Excess tax benefits associated with employee equity plans	$8.87M—	——	——	——
State income taxes – net of federal income tax benefit	——	——	——	——
Effective Income Tax Rate Reconciliation Tax Credits Research	——	——	——	——
Federal State And Local Income Tax Expense Benefit Continuing Operations	$4.43K—	——	——	——
Fees For Issuance Of Common Stock Included In Accounts Payable	——	——	——	——
Fees For Issuance Of Common Stock Included In Accrued Expenses	——	——	——	——
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount	$5.83M—	——	——	——
Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount	-$12.05M—	——	——	——
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount	$461.52K—	——	——	——
Share-based compensation	$1.15M—	——	——	——
Effective Income Tax Rate Reconciliation, Other Adjustments, Amount	-$3.46M—	——	——	——
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount	$812.03K—	——	——	——
Accounts payable	——	——	——	$421.04K—
Accrued liabilities	——	——	$1.48M—	——
Increase (Decrease) in Prepaid Expense	——	——	——	——
Issuance Of Restricted Common Stock	——	——	——	——
Milestone Payments	$2M—	——	——	——
Mutual Fund Security	——	——	——	——
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation	——	——	-$98.46K-100%	$45.02M-76.0%
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation	-$48.14M-193%	$51.56M-0.1%	$51.61M+141%	$21.39M+140%
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation	-$45.79M+11.5%	-$51.76M-0.2%	-$51.66M+50.2%	-$103.8M-13.0%
Net Sales Percentage	——	——	——	——
Number of reportable segments	——	——	——	——
Occupancy and Related Charges	$190.7K-19.5%	$236.9K+5.1%	$225.5K—	——
Operating Loss Carryforward Limitations On Use	$246.41M—	——	——	——
Outstanding Shares Percentage	——	——	——	——
Rent expense	——	——	——	——
Payments for Repurchase of Common Stock	——	——	——	——
Payments Of Stock Issuance Costs	$73.02K-74.6%	$287.09K+192%	$98.46K—	——
Payments to Acquire Short-Term Investments	$83.83M+594%	$12.08M-86.6%	$90.46M+91.3%	$47.29M—
Percenatge Of Net Sales	——	——	——	——
Percentage Of Outstanding Shares	——	——	——	——
Short-term investments sold	$35.69M-43.9%	$63.64M-54.8%	$140.92M+110%	$67.03M-60.3%
Cash received from option exercises	——	——	——	$703.72K+5.3%
Gross realized gains (losses)	-$79.21K-121%	$374.93K+109%	-$4.06M-594%	-$585.52K+7.9%
Realized Lossgain On Shortterm Investments	——	——	——	——
Stock-based compensation	$13.91M-53.9%	$30.18M-31.1%	$43.81M-0.9%	$44.19M+9.1%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period	——	——	——	——
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable	——	——	——	——
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period	——	——	——	——
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Discount For Postvesting Restrictions	——	——	——	——
Share Based Compensation Arrangement By Share Based Payment Award Options Grants Price Per Share	$0.00—	——	——	——
Share Based Compensation Arrangements By Share Based Payment Number Of Shares Granted	——	——	——	——
State And Local Income Tax Expense Benefit Continuing Operations	$4.43K—	——	——	——
Stock Appreciation Rights Compensation	——	$4.47K—	——	——
New issues (in shares)	——	——	——	——
Issuance of common stock in connection with the Spin-Off and reclassification of net parent investment	$93.64M—	——	——	——
Restricted stock acquisition consideration	——	——	——	——
Unrealized Gains	——	——	——	——
Unrealized Losses	——	——	——	——
Unrealized Lossgain On Shortterm Investments	——	——	——	——
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$122.5M+6.2%	$115.36M+2,109%	$5.22M-74.1%	$20.2M-55.9%
Warrant To Purchase Shares Of Common Stock	——	——	——	——
EBIT	-$59.1M+29.6%	-$83.89M+19.1%	-$103.7M+35.7%	-$161.25M-28.3%
EBITDA	——	——	——	——
EBIT	-$59.1M+29.6%	-$83.89M+19.1%	-$103.7M+35.7%	-$161.25M-28.3%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Is Relmada Therapeutics, Inc. profitable?: Relmada Therapeutics, Inc. is not currently profitable: it reported a net loss of $58.9M over the trailing twelve months.
What is Relmada Therapeutics, Inc.'s earnings per share?: Relmada Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-1.11.
Where does Relmada Therapeutics, Inc.'s income statement data come from?: Every line is extracted from Relmada Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.